Menu

Close

A therapeutic combination of two small molecule toxin inhibitors provides pancontinental preclinical efficacy against viper snakebite

Laura-Oana Albulescu, Chunfang Xie, Stuart Ainsworth, Jaffer Alsolaiss, Edouard Crittenden, Charlotte A. Dawson, Rowan Softley, Keirah E. Bartlett, Robert A. Harrison, Jeroen Kool, Nicholas R. Casewell

Preprint posted on May 15, 2020 https://www.biorxiv.org/content/10.1101/2020.05.13.094599v1

Battling the serpent under the flower: potentially dispatching snakebite with a dual-antivenom combination

Selected by Zhang-He Goh

Background of preprint

Snakebite, a neglected tropical disease (NTD) with high rates of morbidity and mortality globally, is currently considered a priority by the World Health Organisation (WHO). Unfortunately, while the WHO hopes to mitigate complications and death arising from snakebite by 2030, antivenoms to date suffer from a few key limitations that preclude their utility.

First, antivenoms currently consist of polyclonal immunoglobulins purified from the plasma or serum of large animals hyperimmunised with snake venoms. As such, antivenoms are generally not highly specific: many antibodies in the polyclonal mix do not bind to venom toxins, thus compromising antivenoms’ efficacies against envenoming by different snake species. The large doses of foreign immunoglobulins often needed for the antivenoms to be effective in turn contribute to a high incidence of adverse reactions. Furthermore, the accessibility of these antivenoms often present difficulties due to the need for a clinical setting for intravenous delivery and for cold chain transport and storage.

To circumvent these limitations, Albulescu et al. aimed to develop a therapeutic small molecule antivenom mixture effective against venoms from vipers found in different geographical regions. In this preprint, the authors explore three drugs for their efficacy against snake venom—the snake venom metalloproteinase (SVMP)-inhibitor marimastat, the phospholipase A2 (PLA2)-inhibitor varespladib, and the snake venom serine protease (SVSP) inhibitor (nafamostat)—and demonstrate the effectiveness of a combination of marimastat and varespladib against envenoming using a mouse model (Fig. 1).

Figure 1. Potential antivenoms explored in this preprint.

Key findings of preprint

Albulescu et al. first tested two SVMP inhibitors, marimastat and batimastat, against venoms of snakes from geographically diverse regions (preprint Fig. 1) using an in vitro kinetic fluorogenic assay (preprint Fig. 2B-C) and a coagulation assay (preprint Fig. 3). The authors found that both antivenoms performed efficaciously, and ultimately selected marimastat over barimastat for further investigations due to marimastat’s superior pharmacokinetics [1] and toxicity profile.

The authors also identified a secondary uninhibited anticoagulant activity in Daboia russelii venom arising from PLA2 toxins, which make up 35% of toxins in D. russelii venom. This led them to investigate the use of PLA2-inhibitor varespladib against D. russelii venom fractions. Indeed, Albulescu et al. showed that a combination of varespladib and marimastat restored clotting profiles to that observed in the control (preprint Fig. S2B).

Having established the rationale for using PLA2 inhibitors (varespladib) and SVMP inhibitors (marimastat), Albulescu et al. further demonstrate the potential utility of SVSP inhibitors (nafamostat) as antivenoms using an in vitro assay. In subsequent tests of the efficacies of varespladib, marimastat, and nafamostat using an in vivo model of envenoming by Echis ocellatus (Table 1), the authors concluded that nafamostat does not contribute significantly to venom neutralisation.

Since nafamostat’s apparent lack of benefit would not balance out the risk of using another drug in combination, Albulescu et al. focussed on the combination of marimastat and varespladib for further development in a preclinical challenge-then-treat model of envenoming that better mimics real life scenarios. After demonstrating that the inhibitor combinations had no apparent adverse effects, the preprint authors showed that the marimastat-varespladib combination significantly protected against the venoms used in the in vivo challenge, as measured by overall survival and quantified TAT levels (preprint Fig. 6A-F).

Table 1. Efficacies of varespladib, marimastat, nafamostat individually or in combination in an in vivo model of envenoming.

What I like about this preprint: the future in an instant

I selected this preprint for two reasons. First, this preprint offers an alternative application of drug repurposing—using drugs that were originally developed for another disease in the treatment of another indication. Previously, I wrote about the utility of drug repurposing in antimicrobial discovery; this preprint shows how drug repurposing can also be applied to antivenom development. Many of the drugs explored in this study, such as varespladib, marimastat, and batimastat, had been advanced to Phase 2 or 3 in clinical trials, so their safety and pharmacokinetic profiles are already somewhat established.

Moreover, this preprint complements the authors’ recently-published work on using metal chelators as potential antivenoms [2]. Drug discovery is unpredictable and difficult: candidates tend to have a high failure rate as they move into clinical trials. Developing a large pool of candidates with different mechanisms of action will therefore help to boost the chance that an effective antivenom is ultimately realised—in all our nights and days to come.

References

[1] Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP, Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers, Br J Clin Pharmacol 45(1) (1998) 21-26.

[2] Albulescu L-O, Hale MS, Ainsworth S, Alsolaiss J, Crittenden E, Calvete JJ, Evans C, Wilkinson MC, Harrison RA, Kool J, Casewell NR, Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite, Science Translational Medicine 12(542) (2020) eaay8314.

Tags: antivenom, snakebite, toxins

Posted on: 29th May 2020

doi: https://doi.org/10.1242/prelights.21419

Read preprint (No Ratings Yet)




  • Have your say

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Sign up to customise the site to your preferences and to receive alerts

    Register here

    preLists in the pharmacology and toxicology category:

    COVID-19 / SARS-CoV-2 preprints

    List of important preprints dealing with the ongoing coronavirus outbreak. See http://covidpreprints.com for additional resources and timeline, and https://connect.biorxiv.org/relate/content/181 for full list of bioRxiv and medRxiv preprints on this topic

     



    List by Gautam Dey, Zhang-He Goh

    1

    Drug use in special populations

    Any drugs that are being used in special populations: Patients with liver and kidney failure, in paediatrics, in geriatrics, and in pregnant or lactating patients. Includes the discovery of factors that could potentially affect drug use in these special populations.

     



    List by Zhang-He Goh

    Toxicology of toxicants, existing therapeutics, and investigational drugs

    Preprints that describe the toxicology of environmental pollutants and existing and upcoming drugs. Includes both toxicokinetics and toxicodynamics, as well as technological improvements that will help in the characterisation of this field.

     



    List by Zhang-He Goh

    Antimicrobials: Discovery, clinical use, and development of resistance

    Preprints that describe the discovery of new antimicrobials and any improvements made regarding their clinical use. Includes preprints that detail the factors affecting antimicrobial selection and the development of antimicrobial resistance.

     



    List by Zhang-He Goh

    Anticancer agents: Discovery and clinical use

    Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.

     



    List by Zhang-He Goh

    Advances in Drug Delivery

    Advances in formulation technology or targeted delivery methods that describe or develop the distribution of small molecules or large macromolecules to specific parts of the body.

     



    List by Zhang-He Goh
    Close